Physician preference for antiepileptic drug concentration testing.

Child neurology involves managing chronic conditions like epilepsy, where medication adherence and monitoring are critical. Antiepileptic drug (AED) concentration testing is a standard practice to ensure therapeutic levels and avoid toxicity. However, traditional blood testing can be stressful for children. Prior research has shown that non-invasive methods are preferred in pediatric care. No prior work had resolved whether child neurologists would value a painless alternative. That uncertainty drove this study to assess physician attitudes toward painless AED monitoring. The gap in understanding physician preference motivated the design of a survey to quantify the perceived value. This paper contributes by reporting on the willingness of child neurologists to adopt a painless method. The findings aim to inform the development of patient-friendly monitoring tools.

This study aimed to evaluate how child neurologists in the U.S. value painless antiepileptic drug concentration monitoring. The specific problem addressed was the lack of data on physician preferences for non-invasive testing methods. The motivation stemmed from the known challenges of traditional blood testing in children. The researchers sought to quantify the time physicians would spend arranging for a painless test. They also wanted to determine how many had used or were aware of saliva-based testing. The study focused on whether a painless method would be adopted if available. The goal was to assess if such a method could meet an unmet clinical need. The findings could influence the development of home-based monitoring systems.

The researchers used a four-item questionnaire to collect data from U.S. members of the Child Neurology Society. The survey asked about the perceived value of painless monitoring and recent use of saliva-based testing. Physicians were asked to estimate the time they would spend arranging for a painless test. The survey also inquired about the availability of such tests and willingness to use them. A total of 945 questionnaires were distributed, and 544 were returned. The data were analyzed to calculate response rates and willingness to use the method. The study did not involve clinical trials or patient data. The approach relied on self-reported attitudes and behaviors.

Of the 544 returned surveys, 55% of respondents reported willingness to spend 10 to 30 minutes arranging for a painless test. A total of 95% would use a painless method if available. When asked about home-based sampling during a seizure or adverse event, 70% would make a significant time commitment. Only 5% would not use the method. Just 2 respondents had ordered a saliva-based test in the past year. Only 6% of physicians perceived such tests as being available. The data suggest strong physician interest in a non-invasive option. The results highlight a potential unmet need for home-based monitoring.

The authors suggest that child neurologists place a high value on painless antiepileptic drug monitoring. The data indicate that a non-invasive method could fulfill an unmet need in pediatric epilepsy care. The researchers propose that such a method would be particularly useful during seizures or adverse events. The low adoption rate of saliva testing suggests limited availability. The study does not claim that all child neurologists would adopt the method. The findings do not imply that painless testing is currently widespread. The authors suggest that improving access to such tests could enhance patient care. The results do not support the claim that all painless methods are equally effective.